BDD Completes Successful Dosing of all Patients, on Schedule, in Head-to-Head Clinical Study of Investigational Subcutaneous Furosemide (SQIN-Furosemide)
BDD Completes Successful Dosing of all Patients, on Schedule, in Head-to-Head Clinical Study of Investigational Subcutaneous Furosemide (SQIN-Furosemide)
GLASGOW, Scotland, Feb. 17, 2026
BDD & SQinnovation today announced all patients have been successfully dosed on schedule, at BDD’s phase 1 clinic in Glasgow, Scotland – in a head-to-head clinical study evaluating SQIN-furosemide, an investigational subcutaneous formulation of furosemide, versus the commercially available furosemide solution for intravenous infusion (Lasix®).
The study is designed to compare the bioavailability, pharmacokinetics (PK) and pharmacodynamics (PD) of SQIN-furosemide against the intravenous comparator, generating additional clinical evidence to support the programme’s continued development and planned regulatory discussions in Europe.
Furosemide is a well-established medicine used worldwide to help manage fluid overload in heart failure, by increasing urine output to remove excess salt and water. While furosemide is commonly administered orally or intravenously, SQIN-furosemide has been developed to enable subcutaneous administration (into the fatty tissue just beneath the skin). This approach has the potential to support treatment outside of hospital, including at-home management, with the aim of helping reduce avoidable admissions for patients experiencing worsening congestion.
Dr Lyn Corry, Principal Investigator at BDD, said: “Dosing our first participant is an important milestone for this programme. We look forward to generating robust comparative PK/PD data from this study and supporting the team as they advance SQIN-furosemide through its next stages of development.”
About the study
This head-to-head clinical study is comparing SQIN-furosemide with intravenously administered furosemide (Lasix®) and assess bioavailability, PK and PD to better characterise the performance of the novel subcutaneous formulation.
About BDD
BDD Pharma Ltd is an integrated UK-based clinical research organisation whose Lean Clinical Development™ pathway combines formulation development, GMP manufacturing and Phase I clinical studies to help accelerate product development.
For further information, contact:
BDD Pharma Ltd.
Tel: +44 (0)141 552 8791
Email: enquiries@bddpharma.com
Website: bddpharma.com